'On consolidated basis
Quarter ended June 2025 compared with Quarter ended June 2024.
Net sales (including other operating income) of Gland Pharma has increased 7.41% to Rs 1505.62 crore. Operating profit margin has jumped from 18.86% to 24.43%, leading to 39.10% rise in operating profit to Rs 367.76 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 35.36% to 36.13%. Purchase of finished goods cost fell from 0.50% to 0.06%. Employee cost decreased from 27.23% to 26.45%. Other expenses fell from 16.66% to 13.53%. Power and Oil fuel cost fell from 3.56% to 2.96%.
Other income rose 11.86% to Rs 57.53 crore. PBIDT rose 34.66% to Rs 425.29 crore. Provision for interest rose 104.63% to Rs 11.5 crore.
PBDT rose 33.39% to Rs 413.79 crore. Provision for depreciation rose 9.88% to Rs 101.05 cr...
Pleaselogin & subscribe to view the full report.
More Reports
|
|